Key Highlights
- Coiled Therapeutics LSE:COIL is shown up 6.25% on 21 September 2026, placing the clinical-stage oncology company among the notable UK-listed movers.
- The company's main focus is AO-252, an orally administered, brain-penetrant TACC3 inhibitor being developed for hard-to-treat cancers.
- A major recent development was the dosing of the first patient with an optimised lipid-based formulation of AO-252 in August 2026.
- Coiled is targeting dose-expansion development in ovarian and prostate cancer, with material clinical data expected during the second half of 2026.
- Earlier clinical data reported an 80% clinical benefit rate in a twice-daily dosing cohort, helping establish the backdrop for the company's next development stage.
- The company raised £8.5 million gross when it moved to AIM in March 2026, providing funding for its clinical programme and development milestones.
Why Is Coiled Therapeutics LSE:COIL in Focus on 21 September 2026?
Coiled Therapeutics LSE:COIL has gained 6.25% on 21 September 2026, bringing the clinical-stage oncology company back into focus as investors monitor progress toward important AO-252 clinical milestones.
Coiled's Investment story changed significantly in March 2026 when it completed the Acquisition of exclusive worldwide rights to AO-252, changed its name from Roquefort Therapeutics and moved its shares to AIM. The transaction was accompanied by an £8.5 million gross fundraising at 10p per share.
The company is now primarily focused on developing precision oncology treatments, making clinical progress rather than conventional Revenue growth the main Factor investors are monitoring.
What Is Driving the 6.25% Move in LSE:COIL?
There is no confirmed single company announcement establishing the exact cause of the 6.25% share-price increase on 21 September 2026.
The move comes, however, against a backdrop of several potentially important clinical catalysts.
The most recent major development was the first patient dosing with a new lipid-based formulation of AO-252 in August. The formulation was designed to improve drug exposure and provide more consistent, dose-proportional absorption compared with the earlier tablet formulation. Coiled reported no treatment-related adverse safety findings from the initial post-dose monitoring.
That development is important because the new formulation is intended to support the company's transition into dose expansion in ovarian and prostate cancer.
Why Is AO-252 So Important for LSE:COIL?
AO-252 is the central asset behind Coiled Therapeutics' current valuation and clinical strategy.
The drug is a small-molecule inhibitor targeting TACC3, a protein associated with several aggressive solid tumours. Coiled describes AO-252 as brain-penetrant, potentially allowing development in settings where penetration into the central nervous system can be relevant.
The drug is currently being evaluated in a Phase I clinical programme in advanced solid tumours.
The company has reported early evidence of tumour reductions in ovarian and endometrial cancer patients at exposures it described as below the anticipated therapeutic range.
For investors, the important issue now is whether the ongoing development programme can produce reproducible efficacy and safety data at appropriate doses.
What Happened With the New AO-252 Formulation?
Coiled announced in August that the first patient had been dosed with the optimised lipid-based formulation of AO-252.
The new formulation uses a lipid-based softgel designed to deliver the drug in a pre-dissolved system. The company developed it after identifying dose-dependent absorption limitations with the previous tablet formulation.
This is a significant development step because improved drug exposure could help the company evaluate AO-252 more effectively during dose expansion.
The formulation is also linked to the company's planned development programme in ovarian and prostate cancer.
Could Upcoming Clinical Data Be the Main Catalyst for LSE:COIL?
Clinical data are likely to remain one of the most important potential catalysts for Coiled Therapeutics.
The company's 2026 roadmap includes expansion cohorts focused on ovarian and prostate cancer, with comprehensive efficacy and safety data expected during the second half of the year.
The company has previously stated that it was targeting up to 30 patients by Q4 2026 in the dose-expansion programme.
This makes the remainder of 2026 an important period for LSE:COIL because investors will be looking for information on response rates, treatment duration, safety, tolerability and drug exposure.
What Did Earlier AO-252 Clinical Data Show?
Earlier data provide the background for the current market interest.
In April 2026, Coiled reported an 80% clinical benefit rate in the twice-daily dosing cohort, compared with 40% in the once-daily cohort. The company also reported tumour stabilisation or regression among evaluable patients in that cohort, with some treatment durations exceeding six months.
These were early-stage findings and came from a limited clinical dataset. The significance of the programme therefore depends on whether subsequent expansion cohorts reproduce the observed signals in larger patient groups.
That distinction is important when assessing the potential impact of future clinical updates.
Why Is Prostate and Ovarian Cancer Development Important?
Coiled has selected prostate and ovarian cancer as key indications for its dose-expansion strategy.
These indications provide a more focused clinical-development pathway than testing AO-252 across a broad range of solid tumours.
The company has also highlighted potential expansion opportunities based on the drug's mechanism and early clinical observations. Its stated 2026 strategy includes dose expansion and additional clinical development designed to establish whether AO-252 can advance toward later-stage trials.
The market will therefore be watching whether the clinical data support continued development in these indications.
Could the New Corporate Broker Appointment Matter for LSE:COIL?
Coiled appointed Shore Capital Stockbrokers as a joint corporate broker on 1 September 2026.
The appointment comes as the company enters a potentially important period of clinical development.
While the broker appointment itself does not establish a reason for the 6.25% share-price move, it forms part of the company's broader capital-markets activity following its AIM admission and transformation into a clinical-stage oncology company.
Investors are more likely to focus on clinical milestones as the key fundamental drivers.
What Is the Financial Position Behind Coiled Therapeutics?
The March 2026 transaction raised £8.5 million gross, with the proceeds intended to fund the company's strategic and clinical objectives and reach key clinical value milestones during 2026 and 2027.
This funding is important because Coiled remains a clinical-stage biotechnology company and therefore depends heavily on its available cash resources to finance research and development.
Future funding requirements, clinical expenditure and the timing of data readouts will remain important considerations.
What Should Investors Watch After the 6.25% Rise?
Following the 21 September 2026 move, the main areas to monitor include:
- Progress of AO-252 dose-expansion cohorts.
- Clinical data from ovarian cancer patients.
- Clinical data from prostate cancer patients.
- Safety and tolerability of the new lipid-based formulation.
- Drug-exposure data following the formulation change.
- Patient recruitment and enrolment progress.
- Potential expansion into additional indications.
- Timing of H2 2026 clinical readouts.
- Cash utilisation and future financing requirements.
- Potential strategic or commercial discussions surrounding AO-252.
The company's own development roadmap identifies the second half of 2026 as a period for important clinical data and potential value-inflection points.
Why Are Investors Watching Coiled Therapeutics LSE:COIL Today?
The 6.25% gain on 21 September 2026 comes as Coiled Therapeutics enters a potentially significant period for its clinical programme.
The company has moved rapidly from its March AIM admission to advancing a new formulation of AO-252 and preparing dose-expansion work in prostate and ovarian cancer.
The immediate market focus is therefore on whether the next clinical data can provide additional evidence regarding AO-252's efficacy, safety and appropriate dosing.
Unlike an established healthcare company where revenue and Earnings may dominate share-price analysis, Coiled remains primarily a clinical-development story. Consequently, trial milestones, patient recruitment, safety findings and efficacy data are likely to remain central to LSE:COIL trading activity.
What Could Be the Next Major Catalyst for LSE:COIL?
The next major focus is likely to be additional clinical information from AO-252, particularly as the company progresses its dose-expansion programme.
The new lipid-based formulation is intended to address earlier absorption limitations, while the planned ovarian and prostate cohorts are designed to generate more focused clinical evidence.
The market will therefore be watching for updates on patient dosing, enrolment, safety and efficacy as the company works toward its anticipated H2 2026 data milestones.
Top of Form
Bottom of Form
_11_19_2026_14_04_21_792016.jpg)
_11_19_2026_14_04_28_358813.jpg)




Please wait processing your request...